A compound represented by formula (3): ##STR00001##
(wherein R.sup.1 represents a C1-C6 alkyl group optionally having one or more halogen atoms, R.sup.2 represents a C1-C6 alkyl group, and m represents an integer of 0 to 3)
can be produced by reacting a C1-C6 alkanesulfinic acid salt optionally having one or more halogen atoms with a compound represented by formula (2): ##STR00002##
(wherein R.sup.2 and m are as defined above)
in the presence of a protonic acid.

A compound represented by formula (3):

##STR00001## (wherein R.sup.1 represents a C1-C6 alkyl group optionally having one or more halogen atoms, R.sup.2 represents a C1-C6 alkyl group, and m represents an integer of 0 to 3) can be produced by reacting a C1-C6 alkanesulfinic acid salt optionally having one or more halogen atoms with a compound represented by formula (2):

##STR00002## (wherein R.sup.2 and m are as defined above) in the presence of a protonic acid.

The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

Disclosed herein are compositions for use in an energy providing devices and methods of preparing such devices. Also included herein is energy providing devices that comprise a charged compound modified substrate or zwitterion-modified substrate or energy providing devices that comprise an electrolyte that comprises a perhalogenatedphenyl azide charged or zwitterionic compound.

The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof. ##STR00001##

The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof. ##STR00001##

The present invention relates to cyclopropyl derivatives of general formula (I), wherein A, R.sup.1, and R.sup.2 are as defined in the specification. The present application also relates to pharmaceutical compositions containing such compounds and to their use in therapy. ##STR00001##

The present invention relates to cyclopropyl derivatives of general formula (I), wherein A, R.sup.1, and R.sup.2 are as defined in the specification. The present application also relates to pharmaceutical compositions containing such compounds and to their use in therapy. ##STR00001##

The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.

##STR00001##